Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a post on X about a paper he co-authuored with colleagues published in Leukemia:
“Delighted to share our brand new review article led by Florian Heidel. The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on AML and MPN.”
Title: The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms
Authors: Michael Kühn, Naveen Pemmaraju, Florian Heidel.
You can read the Full Article in Leukemia.
More posts featuring Naveen Pemmaraju.
